ClinicalTrials.gg
RecruitingNCT07646860Updated Oct 6, 2026

A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)

A Phase 2 interventional study of Sotatercept in Pulmonary Arterial Hypertension, sponsored by Merck Sharp & Dohme LLC. Recruiting at 3 sites in Japan. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 6, 2026Start date movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Planned enrollment
18th of 18
6 · median 44
Started
2026
with 3 others
Phase 2
7 of 18
3 open now
Registered
17th of 18
by date
Lead sponsor
7 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 18th largest by planned enrollment, is one of 4 that started in 2026, is one of 7 in phase 2, and was the 17th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment. Researchers also want to learn what happens to it in a person's body over time and whether it lowers resistance in blood vessels in the lungs.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has pulmonary arterial hypertension (PAH, World Health Organization Group 1) confirmed by a prior right heart catheterization
  • Has idiopathic, heritable, drug- or toxin-induced PAH, connective tissue disease-associated PAH, repaired congenital heart disease-associated PAH, or PAH with coincidental shunt
  • Has PAH classified as World Health Organization Functional Class I, or symptomatic World Health Organization Functional Class II to IV
  • Has been receiving stable standard-of-care background therapy for PAH for at least 90 days
  • Is Japanese

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • History of left-sided heart disease
  • Has severe congenital or developmental abnormalities of the lung, thorax, and/or diaphragm
  • History of Eisenmenger syndrome, Potts shunt, or recent atrial septostomy within 180 days
  • Has unrepaired or residual cardiac shunt with Qp/Qs >1.5
  • Has pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, or overt signs of pulmonary capillary and/or venous involvement
  • PAH associated with portal hypertension
  • Known visceral arteriovenous malformations
  • History of full or partial pneumonectomy
  • Untreated more than mild obstructive sleep apnea
  • History of known pericardial constriction
  • Family history of sudden cardiac death or long syndrome
  • History of symptomatic coronary disease within 6 months or cerebrovascular accident within 3 months
  • Prior treatment with sotatercept or luspatercept
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Sotatercept

    Participants receive sotatercept by subcutaneous injection every 3 weeks (Q3W) for up to approximately 24 weeks while continuing standard-of-care background therapy for PAH. Participants start at a dose of 0.3 mg/kg Q3W, and may titrate up to the target dose of 0.7 mg/kg SC injection Q3W starting at Week 6 based on protocol-defined dose-escalation guidance. After Week 24, participants who meet certain requirements may choose to continue receiving sotatercept for up to 58 months.

    Biological: Sotatercept

Interventions

  • BiologicalSotatercept

    Sotatercept subcutaneous injection every 3 weeks

    Also known as: MK-7962, ACE-011, ActRIIA-IgG1Fc, WINREVAIR®

06

What researchers measure

Primary outcomes

  1. Number of Participants With One or More Adverse Events

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 24 weeks

  2. Number of Participants Who Discontinue Study Intervention Due to an Adverse Event

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 24 weeks

  3. Laboratory Parameter (Hematology): Concentration of Hemoglobin

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The concentration of hemoglobin will be presented.

    Time frame: Up to approximately 24 weeks

  4. Laboratory Parameter (Hematology): Hematocrit

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The hematocrit will be presented.

    Time frame: Up to approximately 24 weeks

  5. Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The RBC count will be presented.

    Time frame: Up to approximately 24 weeks

  6. Laboratory Parameter (Hematology): Reticulocyte Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The reticulocyte count will be presented.

    Time frame: Up to approximately 24 weeks

  7. Laboratory Parameter (Hematology): Platelet Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The platelet count will be presented.

    Time frame: Up to approximately 24 weeks

  8. Blood Pressure (BP)

    BP will be assessed while the participant was seated after a period of rest in a quiet setting with no distractions (eg, television and cell phones).

    Time frame: Up to approximately 24 weeks

  9. Number of Participants with Detectable Anti-Drug Antibodies (ADAs)

    Blood samples will be collected to assess antidrug antibodies to sotatercept. The number of participants with detectable ADAs at any time during the study will be presented.

    Time frame: Up to approximately 24 weeks

  10. Number of Participants with Detectable Neutralizing Antibodies to Sotatercept

    Neutralizing antibody analysis will be performed on blood samples for participants who are confirmed as antidrug antibody-positive. The number of participants with detectable neutralizing antibodies at any time during the study will be presented.

    Time frame: Up to approximately 24 weeks

  11. Serum Trough Concentration (Ctrough) of Sotatercept

    Serum samples collected predose will be used to determine serum trough concentration (Ctrough) of sotatercept.

    Time frame: At designated time points and up to approximately 24 weeks

  12. Change From Baseline in Pulmonary Vascular Resistance Index (PVRI)

    The change from baseline in PVRI will be presented.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Mean Change from Baseline in 6-Minute Walk Distance (6MWD)

    6MWD will be assessed using the 6-minute walk test (6MWT).

    Time frame: Baseline and Week 24

  2. Mean Change from Baseline in N-terminal Prohormone B-type Natriuretic Peptide (NT-proBNP)

    The change from baseline in plasma NT-proBNP levels will be reported.

    Time frame: Baseline and Week 24

  3. Percentage of Participants Who Either Improved or Maintained Their World Health Organization Functional Class (WHO FC)

    The severity of an individual's PAH symptoms will be graded using the WHO FC system. WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). The change from baseline in WHO FC will be classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC.

    Time frame: Baseline and Week 24

  4. Number of Participants With One or More Adverse Events

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From Week 24 up to approximately 58 months

  5. Number of Participants Who Discontinue Study Intervention Due to an Adverse Event

    An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From Week 24 up to approximately 58 months

  6. Laboratory Parameter (Hematology): Concentration of Hemoglobin

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The concentration of hemoglobin will be presented.

    Time frame: From Week 24 up to approximately 58 months

  7. Laboratory Parameter (Hematology): Hematocrit

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The hematocrit will be presented.

    Time frame: From Week 24 up to approximately 58 months

  8. Laboratory Parameter (Hematology): Red Blood Cell (RBC) Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The RBC count will be presented.

    Time frame: From Week 24 up to approximately 58 months

  9. Laboratory Parameter (Hematology): Reticulocyte Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The reticulocyte count will be presented.

    Time frame: From Week 24 up to approximately 58 months

  10. Laboratory Parameter (Hematology): Platelet Count

    Hematological parameters will be investigated in blood samples from participants by means of clinical laboratory assays and evaluated by the investigator. The platelet count will be presented.

    Time frame: From Week 24 up to approximately 58 months

  11. Blood Pressure (BP)

    BP will be assessed while the participant was seated after a period of rest in a quiet setting with no distractions (eg, television and cell phones).

    Time frame: From Week 24 up to approximately 58 months

  12. Number of Participants with Detectable ADAs

    Blood samples will be collected to assess antidrug antibodies to sotatercept. The number of participants with detectable ADAs at any time during the study will be presented.

    Time frame: From Week 24 up to approximately 58 months

  13. Number of Participants with Detectable Neutralizing Antibodies to Sotatercept

    Neutralizing antibody analysis will be performed on blood samples for participants who are confirmed as ADA-positive. The number of participants with detectable neutralizing antibodies at any time during the study will be presented.

    Time frame: From Week 24 up to approximately 58 months

07

Study locations

3 of 3 sites recruiting
  • Osaka Prefectural Hospital Organization Osaka Women's and Children's Hospital ( Site 3203)
    Izumi, Osaka 594-1101, Japan
    Recruiting
    • Study Coordinator · Contact+81-725-56-1260
  • The University of Osaka Hospital ( Site 3201)
    Suita, Osaka 565-0871, Japan
    Recruiting
    • Study Coordinator · Contact+81-6-6879-5111
  • National Center for Child Health and Development ( Site 3202)
    Setagaya City, Tokyo 157-8535, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-3416-0181
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2029, 32 months after the start.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 32 months is close to that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartActual
Sep 17, 2026
Primary completionEst.
May 24, 2029
CompletionEst.
May 16, 2031
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 25, 2026→Sep 17, 2026 (actual)
Oct 6, 2026
Contact
Study contact's phone or email changed: T•••@merck.com→T•••@msd.com. See the current contact
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Start date Sep 25, 2026→Sep 17, 2026 (now actual)
    Contact Study contact's phone or email changed: T•••@merck.com→T•••@msd.com. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07646860
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Sep 17, 2026
Primary completion
May 24, 2029 (estimated)
Completion
May 16, 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion